Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells

Biochemical Pharmacology

Volumn 55, Issue 10, 1998, Pages 1673-1681

  Parker, William B ^a   Allan, Paula W ^a   Shaddix, Sue C ^a   Rose, Lucy M ^a   Speegle, Heath F ^a   Gillespie, G Yancey ^b   Bennett Jr , L Lee ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

2 fluoroadenine; 6 methylpurine; Adenosine triphosphate analogs; E. coli purine nucleoside phosphorylase; Gene therapy

Indexed keywords

2 FLUOROADENINE; 6 METHYLPURINE; NUCLEOSIDE ANALOG; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CYTOTOXICITY; DNA SYNTHESIS; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; ESCHERICHIA COLI; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA SYNTHESIS; SUICIDE GENE;

3T3 CELLS; ADENINE; ANIMALS; CELL DIVISION; CELL LINE; CYCLOHEXIMIDE; DNA; FLUOROURACIL; HUMANS; MICE; NUCLEIC ACID SYNTHESIS INHIBITORS; PROTEIN SYNTHESIS INHIBITORS; PURINES; RNA;

EID: 0032524985     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00034-3     Document Type: Article

References (44)

1. Moolten FL. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1:1994;279-287.
2. Mullen CA. Metabolic suicide genes in gene therapy. Pharmacol Ther. 63:1994;199-207.
3. Culver KW, Blaese RM. Gene therapy for cancer. Trends Genet. 10:1994;174-178.
4. Conners TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2:1995;702-709.
5. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol. 23:1996;31-45.
6. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther. 1:1994;233-238.
7. Hughes BW, Wells AH, Bebok Z, Gadi VK, Garver RI Jr, Parker WB, Sorscher EJ. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 55:1995;3339-3345.
8. Parker WB, King SA, Allan PW, Bennett LL Jr, Secrist JA III, Montgomery JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY, Sorscher EJ. In vivo gene therapy of cancer using E. coli purine nucleoside phosphorylase. Hum Gene Ther. 8:1997;1649-1656.
9. Allan PW, Shaddix SC, Gillespie GY, Bennett LL Jr, Parker WB. Mechanism of action of 6-methylpurine and 2-fluoroadenine. Proc Am Assoc Cancer Res. 38:1997;379.
10. Montgomery JA, Hewson K. Synthesis of potential anticancer agents, XX. 2-Fluoropurines. J Am Chem Soc. 82:1960;463-468.
11. Hershko A, Mamont P, Shields R, Tompkins GM. Pleiotropic response. Nature New Biol. 232:1971;206-211.
12. Bennett LL Jr, Smithers D, Hill DL, Rose LM, Alexander JA. Biochemical properties of the nucleoside of 3-amino-1,5-dihydro-5-methyl-1,4,5,6,8-pentaazaacenaphthylene (NSC-154020). Biochem Pharmacol. 27:1978;233-241.
13. Parker WB, Shaddix SC, Chang C-H, White EL, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist JA III, Bennett LL Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 51:1991;2386-2394.
14. Parker WB, Shaddix SC, Bowdon BJ, Rose LM, Vince R, Shannon WM, Bennett LL Jr. Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effect on cellular metabolism. Antimicrob Agents Chemother. 37:1993;1004-1009.
15. Parker WB, Shaddix SC, Allan PW, Arnett G, Rose LM, Shannon WM, Shealy YF, Montgomery JA, Secrist JA III, Bennett LL Jr. Incorporation of the carbocyclic analog of 2′-deoxyguanosine into the DNA of herpes simplex virus and of HEp-2 cells infected with herpes simplex virus. Mol Pharmacol. 41:1992;245-251.
16. Bennett LL Jr, Smithers D, Ward CT. Inhibition of DNA synthesis in mammalian cells by actidione. Biochim Biophys Acta. 87:1964;60-69.
17. Myers CE. The pharmacology of the fluoropyrimidines. Pharmacol Rev. 33:1981;1-15.
18. Parker WB, Cheng Y-C. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther. 48:1990;381-395.
19. Hill DL, Straight S, Allan PW. Use of Tetrahymena pyriformis to evaluate the effects of purine and pyrimidine analogs. J Protozool. 17:1970;619-623.
20. Parks RE Jr, Brown PR. Incorporation of nucleosides into the nucleotide pools of human erythrocytes. Adenosine and its analogs. Biochemistry. 12:1973;3294-3302.
21. Agarwal KC, Parks RE. Adenosine analogs and human platelets. Effects on nucleotide pools and the aggregation phenomenon. Biochem Pharmacol. 24:1975;2239-2248.
22. Parks RE Jr, Crabtree GW, Kong CM, Agarwal RP, Agarwal KC, Scholar EM. Incorporation of analog purine nucleosides into the formed elements of human blood, erythrocytes, platelets, and lymphocytes. Ann NY Acad Sci. 255:1975;412-434.
23. Shigeura HT, Boxer GE, Sampson SD, Meloni ML. Metabolism of 2-fluoroadenosine by Ehrlich ascites cells. Arch Biochem Biophys. 111:1965;713-719.
24. Avramis VI, Plunkett W. 2-Fluoro-ATP A toxic metabolite of 9-β-D-arabinosyl-2-fluoroadenine . Biochem Biophys Res Commun. 113:1983;35-43.
25. Zimmerman TP, Deeprose RD, Wolberg G, Duncan GS. Metabolic formation of nucleoside-modified analogues of S-adenosylmethionine. Biochem Biophys Res Commun. 91:1979;997-1004.
26. Zimmerman TP, Rideout JL, Wolberg G, Duncan GS, Elion GB. 2-Fluoroadenosine 3′:5′-monophosphate. A metabolite of 2-fluoroadenosine in mouse cytotoxic lymphocytes. J Biol Chem. 251:1976;6757-6766.
27. Zimmerman TP, Wolberg G, Duncan GS, Rideout JL, Beachman LM III, Krenitsky TA, Elion GB. Inhibition of lymphocyte-mediated cytolysis by 2-fluoroadenosine - Evidence for two discrete mechanisms of drug action. Biochem Pharmacol. 27:1978;1731-1737.
28. Bennett LL Jr, Vail MH, Chumley S, Montgomery JA. Activity of adenosine analogs against a cell culture, line resistant to 2-fluoroadenine. Biochem Pharmacol. 15:1966;1719-1728.
29. Tuttle JV, Krenitsky TA. Purine phosphoribosytransferases from Leishmania donovani. J Biol Chem. 255:1980;909-916.
30. Parker WB, Bapat AR, Shen J-X, Townsend AJ, Cheng Y-C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol. 34:1988;485-491.
31. Cheng YC, Grill SP, Dutschman GE, Nakayama K, Bastow KF. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes virus compound, in herpes simplex virus-infected cells. J Biol Chem. 258:1983;12460-12464.
32. Reid R, Mar E-C, Huang E-S, Topal MD. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human α and human β polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem. 263:1988;3898-3904.
33. Balzarini J, Bohman C, DeClercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-1(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem. 268:1993;6332-6337.
34. Ilsley DD, Lee SH, Miller WH, Kutcha RD. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry. 34:1995;2504-2510.
35. Bruce WR, Meeker BE. Comparison of the sensitivity of hematopoietic colony-forming cells in different proliferative states to 5-fluorouracil. J Natl Cancer Inst. 38:1967;401-405.
36. Tannock IF. Principles of cell proliferation Cell kinetics in cancer . Devita VJ, Hellman S, Rosenberg S. Principles and Practice of Oncology. 1989;3-13 L.B. Lippincott, Philadelphia.
37. Bass BL. The dsRNA unwinding/modifying activity Fact and fiction . Semin Dev Biol. 3:1992;425-433.
38. Skipper HE, Montgomery JA, Thomson JR, Schabel FM Jr. Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms. Cancer Res. 19:1959;425-437.
39. Davidson IWF, Fellig J. Cellular conversion of methylpurine to an active analog of ATP. Fedn Proc. 21:1962;160.
40. Bennett LL Jr, Smithers D. Feedback inhibition of purine biosynthesis in H. EP. #2 cells by adenine analogs. Biochem Pharmacol. 13:1964;1331-1339.
41. Leonhardt K, Anke T. 6-Methylpurine, 6-methyl-9-β-D-ribofuranosylpurine, and 6-hydroxymethyl-9-β-D-ribofuranosylpurine as antiviral metabolites of Collybia maculata (Basidiomycetes). Z Naturforsch. 42C:1987;420-424.
42. Benson CE, Love SH, Remy CN. Inhibition of de novo purine biosynthesis and interconversion by 6-methylpurine in Escherichia coli. J Bacteriol. 101:1970;872-880.
43. Miller JH, Kempner ES. Effects of an adenine analog on yeast metabolism. Biochim Biophys Acta. 76:1963;333-340.
44. Dewey VC, Heinrich MR, Markees DG, Kidder GW. Multiple inhibition by 6-methylpurine. Biochem Pharmacol. 3:1960;173-180.